Erythrocytosis and thromboembolic events in transgender individuals receiving gender-affirming testosterone

Erythrocytosis is a well-recognized consequence of exogenous testosterone, however its prevalence and contributions to thrombosis remain unknown in the context of gender-affirming hormonal therapy. We undertook a retrospective study of transgender and non-binary (TGNB) adults receiving exogenous testosterone. In the retrospective sample, 923 transgender individuals receiving testosterone were identified with 519 having documented pre- and post-testosterone hemoglobin and hematocrit (Hgb/Hct). The mean peak Hgb/Hct was 15.7  g/dL, and 47.0%.

Source: Thrombosis Research - September 18, 2021 Category: Hematology Authors: Michael Oakes, Asad Arastu, Catherine Kato, Julia Somers, Hannah D. Holly, Benjamin K. Elstrott, Geolani W. Dy, Tia C.L. Kohs, Rishi R. Patel, Owen J.T. McCarty, Thomas G. DeLoughery, Christina Milano, Vikram Raghunathan, Joseph J. Shatzel Tags: Letter to the Editors-in-Chief Source Type: research